Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Barrett

Showing results (641-650 of 693) with videos related to

Pageof 70
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|August 9, 2007
3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumideMagda F Morton, Terrance D Barrett, Wen Yan, et al.
Journal of Biomolecular Screening|June 6, 2009
Characterization of a robust enzymatic assay for inhibitors of 2-oxoglutarate-dependent hydroxylasesKimon C Kanelakis, Heather L Palomino, Lina Li, et al.
Blood Advances|June 4, 2026
Phase 2a randomized study to evaluate sapablursen in patients with non-transfusion dependent β-thalassemia intermediaAli Taher, Michael D Diamantidis, Antonis Kattamis, et al.
Clinical and Experimental Immunology|September 28, 2018
Blood clotting and traumatic injury with shock mediates complement-dependent neutrophil priming for extracellular ROS, ROS-dependent organ injury and coagulopathyC D Barrett, A T Hsu, C D Ellson, et al.
Transfusion|March 11, 2026
Whole blood storage time impairs clot strength with minimal change in functional fibrinogen concentrationElizabeth R Maginot, Nicolle K Barmettler, Flobater I Gawargi, et al.
Bioorganic & Medicinal Chemistry|February 22, 2008
Discovery of potent cholecystokinin-2 receptor antagonists: elucidation of key pharmacophore elements by X-ray crystallographic and NMR conformational analysisMark D Rosen, Michael D Hack, Brett D Allison, et al.
Nature Medicine|April 11, 2017
A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse modelsChao Shan, Antonio E Muruato, Bruno T D Nunes, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 16, 2011
JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailabilityMagda F Morton, Terrance D Barrett, Jamie Freedman, et al.
Thrombosis and Haemostasis|March 25, 2025
Hyperfibrinolysis is Associated with Complement Activation Following TraumaChristopher D Barrett, Elizabeth R Maginot, Ernest E Moore, et al.
Journal of Medicinal Chemistry|May 18, 2007
Synthesis and biological studies of novel 2-aminoalkylethers as potential antiarrhythmic agents for the conversion of atrial fibrillationBertrand Plouvier, Gregory N Beatch, Grace L Jung, et al.
Pageof 70

Showing results (641-650 of 693) with videos related to

Sort By:
Pageof 70
The Journal of Pharmacology and Experimental Therapeutics|August 9, 2007
3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumideMagda F Morton, Terrance D Barrett, Wen Yan, et al.
Journal of Biomolecular Screening|June 6, 2009
Characterization of a robust enzymatic assay for inhibitors of 2-oxoglutarate-dependent hydroxylasesKimon C Kanelakis, Heather L Palomino, Lina Li, et al.
Blood Advances|June 4, 2026
Phase 2a randomized study to evaluate sapablursen in patients with non-transfusion dependent β-thalassemia intermediaAli Taher, Michael D Diamantidis, Antonis Kattamis, et al.
Clinical and Experimental Immunology|September 28, 2018
Blood clotting and traumatic injury with shock mediates complement-dependent neutrophil priming for extracellular ROS, ROS-dependent organ injury and coagulopathyC D Barrett, A T Hsu, C D Ellson, et al.
Transfusion|March 11, 2026
Whole blood storage time impairs clot strength with minimal change in functional fibrinogen concentrationElizabeth R Maginot, Nicolle K Barmettler, Flobater I Gawargi, et al.
Bioorganic & Medicinal Chemistry|February 22, 2008
Discovery of potent cholecystokinin-2 receptor antagonists: elucidation of key pharmacophore elements by X-ray crystallographic and NMR conformational analysisMark D Rosen, Michael D Hack, Brett D Allison, et al.
Nature Medicine|April 11, 2017
A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse modelsChao Shan, Antonio E Muruato, Bruno T D Nunes, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 16, 2011
JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailabilityMagda F Morton, Terrance D Barrett, Jamie Freedman, et al.
Thrombosis and Haemostasis|March 25, 2025
Hyperfibrinolysis is Associated with Complement Activation Following TraumaChristopher D Barrett, Elizabeth R Maginot, Ernest E Moore, et al.
Journal of Medicinal Chemistry|May 18, 2007
Synthesis and biological studies of novel 2-aminoalkylethers as potential antiarrhythmic agents for the conversion of atrial fibrillationBertrand Plouvier, Gregory N Beatch, Grace L Jung, et al.
Pageof 70